Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
复制标题
DOI：
10.1111/dom.12572
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
Johansen OE
中科院分区：
文献类型：
--
作者：
Chilton R;Tikkanen I;Cannon CP;Crowe S;Woerle HJ;Broedl UC;Johansen OE
目的：探讨恩格列净对2型糖尿病（T2DM）患者血压（BP）及动脉僵硬和血管阻力指标的影响。我们对一项接受12周恩帕列净治疗的T2DM合并高血压患者的III期试验数据和4项接受24周恩帕列净治疗的T2DM患者的III期试验数据进行了事后分析（队列1，n = 823；队列2，n = 2477）。采用24小时血压监测（队列1）或坐式办公室测量（队列2）测量血压。依帕列净降低了两组患者的收缩压（SBP）和舒张压（与安慰剂相比p < 0.001），但没有增加心率。与安慰剂相比，Empagliflozin降低脉压（PP，与安慰剂相比调整后的平均差值为- 2.3 mmHg；队列2:- 2.3 mmHg）、平均动脉压（MAP，队列1，- 2.3 mmHg；队列2，- 2.1 mmHg）和双产品（队列1，- 385 mmHg × bpm；队列2，- 369 mmHg × bpm）均p < 0.001。在队列1中，恩格列净有降低动态动脉僵硬指数（AASI）的趋势（与安慰剂相比p = 0.059）。队列2未测量AASI。亚组分析显示，在队列1中，随着基线收缩压的增加，PP的降低幅度更大（p = 0.092）。在队列2中，基线收缩压较高的患者MAP下降幅度更大（p = 0.027），老年患者PP下降幅度更大（p = 0.011）。恩格列净降低血压，对动脉僵硬和血管阻力指标有良好的影响。
To determine the effects of empagliflozin on blood pressure (BP) and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes mellitus (T2DM). We conducted a post hoc analysis of data from a phase III trial in patients with T2DM and hypertension receiving 12 weeks' empagliflozin and four phase III trials in patients with T2DM receiving 24 weeks' empagliflozin (cohort 1, n = 823; cohort 2, n = 2477). BP was measured using 24‐h BP monitoring (cohort 1) or seated office measurements (cohort 2). Empagliflozin reduced systolic BP (SBP) and diastolic BP in both cohorts (p < 0.001 vs placebo), without increasing heart rate. Empagliflozin reduced pulse pressure (PP; adjusted mean difference vs placebo cohort 1: −2.3 mmHg; cohort 2: −2.3 mmHg), mean arterial pressure (MAP; cohort 1, −2.3 mmHg; cohort 2, −2.1 mmHg) and double product (cohort 1, −385 mmHg × bpm; cohort 2, −369 mmHg × bpm) all p < 0.001 vs placebo. There was a trend towards a reduction in the ambulatory arterial stiffness index (AASI) with empagliflozin in cohort 1 (p = 0.059 vs placebo). AASI was not measured in cohort 2. Subgroup analyses showed that there were greater reductions in PP with increasing baseline SBP in cohort 1 (p = 0.092). In cohort 2, greater reductions in MAP were achieved in patients with higher baseline SBP (p = 0.027) and greater reductions in PP were observed in older patients (p = 0.011). Empagliflozin reduced BP and had favourable effects on markers of arterial stiffness and vascular resistance.
登录
查看更多内容
影响因子：
2.1
作者：
Jung CH;Jung SH;Kim KJ;Kim BY;Kim CH;Kang SK;Mok JO
通讯作者：
Mok JO
影响因子：
2.4
作者：
Inzucchi SE;Zinman B;Wanner C;Ferrari R;Fitchett D;Hantel S;Espadero RM;Woerle HJ;Broedl UC;Johansen OE
通讯作者：
Johansen OE
DOI：
10.1161/hypertensionaha.109.147850
发表时间：
2010-04
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Dengo AL;Dennis EA;Orr JS;Marinik EL;Ehrlich E;Davy BM;Davy KP
通讯作者：
Davy KP
DOI：
10.1016/j.ecl.2013.09.005
发表时间：
2014-03
影响因子：
4.5
作者：
Lastra, Guido;Syed, Sofia;Kurukulasuriya, L. Romayne;Manrique, Camila;Sowers, James R.
通讯作者：
Sowers, James R.
影响因子：
2.8
作者：
Kodama, Satoru;Horikawa, Chika;Sone, Hirohito
通讯作者：
Sone, Hirohito